We report the case of a 48-year-old woman who presented to neurosurgery consultation with a five-month history of progressive headache, vomiting, vertigo, and gait instability. Neurologic examination also revealed a subtle bradypsychia. Non-enhanced CT (Philips Incisive CT) showed a large right parietal mass with gross calcifications. Serious doubts about intra- or extra-axial origin of the lesion arose. Nevertheless, the detection of a subtle underlying hyperostotic spicule on the inner table revealed the extra-axial nature of the lesion. Brain MRI (Philips Ingenia 1.5 T) confirmed an expansive-lobulated mass in the right parietal region with mild peripheral edema. It was hypointense on T1-weighted images (WI) and hyperintense with foci of low signal intensity on T2-WI. A partial CSF-cleft and heterogeneous gadolinium enhancement with an internal honey-comb pattern could also be assessed. It showed a strikingly low cerebral blood volume (CBV) on dynamic susceptibility contrast- perfusion-weighted imaging (DSC-PWI). There were no signs of diffusion restriction. With an extra-axial location in mind, spectroscopy did not uncover any helpful specific biomarkers such as presence of alanine for meningioma, high myo-inositol for solitary fibrous tumor-hemangiopericytoma (SFT-HPC), or high mobile lipids for metastasis. Total neurosurgical resection of the tumor was performed, confirming an extra-axial origin. Histology demonstrated a moderate degree of cellularity with chondroid matrix, chondrocytes of low-to-moderate atypia, binucleated forms, and tumor necrosis. Pathology led to the final diagnosis of conventional dural chondrosarcoma grade II, a malignant entity in the 2020 WHO classification of chondrogenic bone tumors []. Finally, negative whole-body positron-emission-tomography-CT confirmed the extraosseous primary origin. The patient was treated with adjuvant radiotherapy following surgery. Clinical follow-up revealed an incomplete right hemianopsia as a sequala. The first follow-up MRI 2 months after surgery showed no signs of tumor recurrence.